Neuromelanin can protect against iron‐mediated oxidative damage in system modeling iron overload of brain aging and Parkinson’s disease

In Parkinson’s disease (PD), dopamine neurons containing neuromelanin selectively degenerate. Neuromelanin binds iron and accumulates in aging. Iron accumulates in reactive form during aging, PD, and is involved in neurodegeneration. It is not clear how the interaction of neuromelanin and iron can be protective or toxic by modulating redox processes. Here, we investigated the interaction of neuromelanin from human substantia nigra with iron in the presence of ascorbic acid, dopamine, and hydrogen peroxide. We observed that neuromelanin blocks hydroxyl radical production by Fenton’s reaction, in a dose‐dependent manner. Neuromelanin also inhibited the iron‐mediated oxidation of ascorbic acid, thus sparing this major antioxidant molecule in brain. The protective effect of neuromelanin on ascorbate oxidation occurs even in conditions of iron overload into neuromelanin. The blockade of iron into a stable iron–neuromelanin complex prevents dopamine oxidation, inhibiting the formation of neurotoxic dopamine quinones. The above processes occur intraneuronally in aging and PD, thus showing that neuromelanin is neuroprotective. The iron–neuromelanin complex is completely decomposed by hydrogen peroxide and its degradation rate increases with the amount of iron bound to neuromelanin. This occurs in PD when extraneuronal iron–neuromelanin is phagocytosed by microglia and iron–neuromelanin degradation releases reactive/toxic iron.

[1]  F. García-Cánovas,et al.  Improvement of a Continuous Spectrophotometric Method for Determining the Monophenolase and Diphenolase Activities of Mushroom Polyphenol Oxidase , 1997 .

[2]  D. Sulzer,et al.  Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease , 2007, Trends in Neurosciences.

[3]  B. Halliwell,et al.  1 Iron toxicity and oxygen radicals , 1989 .

[4]  D. Sulzer,et al.  Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour , 2001, Molecular pathology : MP.

[5]  Rabi Tawil,et al.  Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights. , 2005, Journal of neuropathology and experimental neurology.

[6]  T. Shima,et al.  Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study. , 1997, Free radical biology & medicine.

[7]  G. Deuschl,et al.  Activation of microglia by human neuromelanin is NF‐κB‐dependent and involves p38 mitogen‐activated protein kinase: implications for Parkinson's disease , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  G. Edwards,et al.  The surface oxidation potential of human neuromelanin reveals a spherical architecture with a pheomelanin core and a eumelanin surface , 2006, Proceedings of the National Academy of Sciences.

[9]  H. Schipper Brain iron deposition and the free radical-mitochondrial theory of ageing , 2004, Ageing Research Reviews.

[10]  Peter T. Lansbury,et al.  Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct , 2001, Science.

[11]  D. Radice,et al.  Iron and Other Metals in Neuromelanin, Substantia Nigra, and Putamen of Human Brain , 1994, Journal of neurochemistry.

[12]  E. Hirsch,et al.  Neuromelanin associated redox‐active iron is increased in the substantia nigra of patients with Parkinson's disease , 2003, Journal of neurochemistry.

[13]  T. Sarna,et al.  The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems. , 1995, Biochimica et biophysica acta.

[14]  P. Arosio,et al.  Characterization of the l-ferritin variant 460InsA responsible of a hereditary ferritinopathy disorder , 2006, Neurobiology of Disease.

[15]  A. Graybiel,et al.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease , 1988, Nature.

[16]  D. Selkoe,et al.  Dopamine covalently modifies and functionally inactivates parkin , 2005, Nature Medicine.

[17]  H. Schipper Glial HO-1 expression, iron deposition and oxidative stress in neurodegenerative diseases , 1999, Neurotoxicity Research.

[18]  Wade K. Smith,et al.  Disease‐specific patterns of locus coeruleus cell loss , 1992, Annals of neurology.

[19]  J. Langston,et al.  Iron‐mediated bioactivation of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) in glial cultures , 1995, Glia.

[20]  R. Silber,et al.  A spectrophotometric assay for dehydroascorbate reductase. , 1983, Analytical biochemistry.

[21]  P. Riederer,et al.  Structural Characteristics of Human Substantia Nigra Neuromelanin and Synthetic Dopamine Melanins , 2000, Journal of neurochemistry.

[22]  Subramanian Rajagopalan,et al.  Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo A Novel Therapy for Parkinson's Disease , 2003, Neuron.

[23]  J. Langston,et al.  Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine exposure , 1999, Annals of neurology.

[24]  J. Segura-Aguilar,et al.  Aminochrome as a preclinical experimental model to study degeneration of dopaminergic neurons in Parkinson’s disease , 2007, Neurotoxicity Research.

[25]  E. Hirsch,et al.  Blood vessels change in the mesencephalon of patients with Parkinson's disease , 1999, The Lancet.

[26]  P. Riederer,et al.  Iron-binding characteristics of neuromelanin of the human substantia nigra. , 2003, Biochemical pharmacology.

[27]  D. Sulzer,et al.  Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics , 2003, Trends in Neurosciences.

[28]  N. Turro,et al.  Amyloid β and neuromelanin—Toxic or protective molecules? The cellular context makes the difference , 2006, Progress in Neurobiology.

[29]  K. Jellinger,et al.  Iron‐Melanin Complex in Substantia Nigra of Parkinsonian Brains: An X‐Ray Microanalysis , 1992, Journal of neurochemistry.

[30]  Alberto Gatti,et al.  The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[31]  B. Bergamasco,et al.  EPR investigations of the iron domain in neuromelanin. , 1997, Biochimica et biophysica acta.

[32]  H. M. Swartz,et al.  Interaction of neuromelanin and iron in substantia nigra and other areas of human brain , 1996, Neuroscience.

[33]  K. Jellinger,et al.  The Neuropathologic Basis of Different Clinical Subgroups of Parkinson's Disease , 1991, Journal of neuropathology and experimental neurology.

[34]  C. Morris,et al.  Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease , 2001, Nature Genetics.

[35]  L. Casella,et al.  Tyrosinase-catecholic substrates in Vitro model: kinetic studies on the o-quinone/o-semiquinone radical formation☆ , 1997 .

[36]  J. Connor,et al.  Iron, brain ageing and neurodegenerative disorders , 2004, Nature Reviews Neuroscience.

[37]  O. Rascol,et al.  Intracellular Ferritin Accumulation in Neural and Extraneural Tissue Characterizes a Neurodegenerative Disease Associated with a Mutation in the Ferritin Light Polypeptide Gene , 2004, Journal of neuropathology and experimental neurology.

[38]  S. Ito,et al.  Interaction of Human Substantia Nigra Neuromelanin with Lipids and Peptides , 2000, Journal of neurochemistry.

[39]  K. Vrana,et al.  Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase , 1998, Journal of neuroscience research.

[40]  B. Bergamasco,et al.  Modifications of the iron–neuromelanin system in Parkinson's disease , 2006, Journal of neurochemistry.

[41]  K. Wakamatsu,et al.  The structure of neuromelanin as studied by chemical degradative methods , 2003, Journal of neurochemistry.

[42]  J. Loike,et al.  Macrophages adhere to glucose-modified basement membrane collagen IV via their scavenger receptors. , 1994, The Journal of biological chemistry.

[43]  M. Rice Ascorbate regulation and its neuroprotective role in the brain , 2000, Trends in Neurosciences.

[44]  J. B. Justice,et al.  Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter , 2001, Journal of neurochemistry.

[45]  R. Floyd,et al.  Use of salicylate with high pressure liquid chromatography and electrochemical detection (LCED) as a sensitive measure of hydroxyl free radicals in adriamycin treated rats. , 1986, Journal of free radicals in biology & medicine.

[46]  T. Sarna,et al.  Antioxidant action of neuromelanin: the mechanism of inhibitory effect on lipid peroxidation. , 1995, Archives of biochemistry and biophysics.

[47]  C. Marsden,et al.  Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease , 1989, Journal of neurochemistry.

[48]  Alberto Albertini,et al.  The neuromelanin of human substantia nigra: physiological and pathogenic aspects. , 2004, Pigment cell research.